Enlivex Ltd(ENLV) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 29 at 5:50 PM ET (Korea 10/30 06:50)
Full metrics table
| Index | - | P/E | 0.01 | EPS (ttm) | 382.12 | Insider Own | 89.54% | Shs Outstand | 16.8M | Perf Week | -20.31% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 0.2M | Perf Month | -68.43% |
| Enterprise Value | 0.02B | PEG | - | EPS next Q | -4.48 | Inst Own | 1.16% | Short Float | 6.22% | Perf Quarter | -92.4% |
| Income | 1.24B | P/S | - | EPS this Y | - | Inst Trans | 0.42% | Short Ratio | 0.15 | Perf Half Y | -98.71% |
| Sales | 0.00B | P/B | 0.01 | EPS next 5Y | 72.14% | ROA | 104.94% | Short Interest | 0.01M | Perf YTD | -98.49% |
| Book/sh | 231.6 | P/C | 0.69 | EPS past 3/5Y | - | ROE | 126.17% | 52W High | -99.42% ($434.40) | Perf Year | -99.01% |
| Cash/sh | 3.67 | P/FCF | - | Sales past 3/5Y | - | ROIC | 31.69% | 52W Low | 14.67% ($2.21) | Perf 3Y | -99.2% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 3852.04% | Gross Margin | - | Volatility(W/M) | 13.74% 16.71% | Perf 5Y | -99.87% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.93 | Perf 10Y | -99.98% |
| Dividend Ex-Date | - | Quick Ratio | 119.39 | EPS Q/Q | 4589.61% | Profit Margin | - | RSI (14) | 14.18 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 119.39 | Sales Q/Q | - | SMA20 | -32.54% ($3.77) | Beta | 1.49 | Target Price | $1280 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/08/24 | SMA50 | -76.93% ($11.01) | Rel Volume | 0.78 | Prev Close | $2.61 |
| Employees | 34 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -98.19% ($140.33) | Avg Volume(3M) | 0.06M | Price | $2.54 |
| IPO | 2014/7/31 | Option/Short | No/Yes | Trades | 897 | Volume | 50,176 | Change | -2.68% |
🧬 Enlivex is a clinical-stage macrophage reprogramming immunotherapy company based in Israel. It is developing cell therapies targeting diseases that require immune modulation, such as osteoarthritis and sepsis, with its lead candidate Allocetra at the forefront. As a development-stage biotech that has not yet generated commercial revenue, its corporate value is shaped by progress in its clinical pipeline and the flow of its funding.
Over the past 1 year, on the lower side
99% below its 1-year high.
Traded less than usual. That is 78% of its average volume.
ENLV earns at a steady pace
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +72.1% this year.
Tap to view numbers
Within its industry, it looks cheap
For a company earning $100 a year, you would pay $1. Peers typically go for $1,433.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.9%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 1.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
IZRL ARK Israel Innovative Technology ETF 0.01% 
QQQS Invesco NASDAQ Future Gen 200 ETF <0.01% It ranks #550 of 594 in the industry
Based on market cap of $4M.
FAQ
What kind of company is ENLV?
ENLV belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ENLV?
The market cap of ENLV is approximately $4M, ranking 5,681 within its sector.
What is the P/E ratio of ENLV?
ENLV has a P/E ratio of approximately 0.0x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for ENLV?
ENLV has recorded a 52-week high of $434.40 and a low of $2.21.
